Research progress on immune checkpoint inhibitors combined with stereotactic ablative body radiotherapy for advanced non-small cell lung cancer
Wang Xiaofeng1, Bai Hui2,Huang Guoding2, Liu Feng3, Yao Yuan3, Liang Jun1,4
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2Department of Radiation Oncology, Hainan West Central Hospital, Danzhou 571799, China; 3Department of Radiotherapy, the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China; 4Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China
Abstract：The effect of radiotherapy on anti-tumor immunity is bidirectional, immunotherapy, especially the combination of immune checkpoint inhibitors (ICIs) and radiotherapy, can produce synergistic effects on anti-tumor immunity. Compared with conventional radiotherapy, stereotactic ablative body radiotherapy (SABR) can achieve high-precision and high-dose irradiation on target lesions, and has stronger anti-tumor immune activation effect. At the same time, due to the steep dose gradient, SABR can better protect the surrounding normal tissues, which is an effective means for the rapid control of local lesions in advanced non-small cell lung cancer (NSCLC). ICIs are an important component of standard treatment for advanced NSCLC. There is growing evidence that SABR in combination with ICIs can benefit patients with advanced NSCLC. This article reviews the biological basis and clinical research progress on the combination of these two therapies, aiming to provide reference for the domestic counterparts to better use this new treatment model.
Wang Xiaofeng,Bai Hui,Huang Guoding et al. Research progress on immune checkpoint inhibitors combined with stereotactic ablative body radiotherapy for advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(3): 298-302.
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. DOI:10.3322/caac.21654. [2] Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer[J]. Lancet, 2016, 387(10026):1354-1356. DOI:10.1016/S0140-6736(15)01125-3. [3] Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy[J]. Clin Cancer Res, 2015, 21(4):687-692. DOI:10. 1158/1078-0432. CCR-14-1860. [4] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. DOI 10. 1056/ NEJMoa1810865. [5] Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189:pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(14):1505-1517. DOI:10.1200/JCO.19.03136. [6] Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamousNSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. DOI:10.1056/NEJMoa1716948. [7] Lu S, Wang J, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced non-small cell lung cancer:2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)[J]. Lung Cancer, 2021, 152(1):7-14. DOI:10.1016/j.lungcan.2020.11.013. [8] Boyer M,şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%:randomized, double-blind phase Ⅲ KEYNOTE-598 study[J]. J Clin Oncol, 2021, 39(21):2327-2338. DOI:10.1200/jco.20.03579. [9] Parikh F, Duluc D, Imai N, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer[J]. Cancer Res, 2014, 74(24):7205-7216. DOI:10.1158/0008-5472. CAN-14-1913. [10] Lee BM, Byun HK, Seong J. Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer[J]. Radiother Oncol, 2020, 151(1):82-87. DOI:10.1016/j.radonc.2020.07.026. [11] Sun GY, Wang SL, Song YW, et al. Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer:a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):277-285. DOI:10.1016/j.ijrobp.2020.02.633. [12] Royce TJ, Mavroidis P, Wang K, et al. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer[J]. Int J Radiat Oncol Biol Phys. 2021, 110(1):227-236. DOI:10.1016/j.ijrobp.2020.08.014. [13] Siva S, MacManus MP, Martin RF, et al. Abscopal effects of radiation therapy:a clinical review for the radiobiologist[J]. Cancer Lett, 2015, 356(1):82-90. DOI:10.1016/j.canlet.2013.09.018. [14] Lai JZ, Zhu YY, Liu Y, et al. Abscopal effects of local radiotherapy are dependent on tumor immunogenicity[J]. Front Oncol, 2021, 11:690188. DOI:10.3389/fonc.2021.690188. [15] Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD+8 T cells via dendritic cell activation[J]. J Immunol, 2012, 189(2):558-566. DOI:10.4049/jimmunol.1200563. [16] Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma[J]. Blood, 2013, 121(2):251-259. DOI:10.1182/blood-2012-05-432393. [17] Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):212-224. DOI:10.1016/j.ijrobp.2020.05.002. [18] Camphausen K, Moses MA, Ménard C, et al. Radiation abscopal antitumor effect is mediated through p53[J]. Cancer Res, 2003, 63(8):1990-1993. [19] Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009, 15(17):5379-5388. DOI:10.1158/1078-0432. CCR-09-0265. [20] Zhao D, Zhu GY, Yu R, et al. Cellular immunity enhanced after SABR, but decreased after conventional fractionated radiation therapy of non-small cell lung cancer patients[J]. Int J Radiat Oncol Biol Phys, 2015, 93(3s):189. DOI:10.1016/j.ijrobp.2015.07.452. [21] Dammeijer F, Lievense LA, Veerman GD, et al. Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer:a systematic review and meta-analysis[J]. J Clin Oncol, 2016, 34(26):3204-3212. DOI:10.1200/JCO.2015.66.3955. [22] Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR):a curative approach?[J]. Nat Rev Clin Oncol, 2016, 13(8):516-524. DOI:10.1038/nrclinonc.2016.30. [23] Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4):916-925. DOI:10.1016/j.ijrobp.2017.11.041. [24] Yuan Z, Fromm A, Ahmed KA, et al. Radiotherapy rescue of a Nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung[J]. J Thorac Oncol, 2017, 12(9):e135-e136. DOI:10.1016/j.jtho.2017.04.029. [25] Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer:a phase 2 trial[J]. JAMA Oncol, 2019, 5(9):1283-1290. DOI:10.1001/jamaoncol.2019.1449. [26] Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab a lone on tumor response in patients with advanced non-small cell lung cancer:results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI:10.1001/jamaoncol.2019.1478. [27] Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001001. DOI:10.1136/jitc-2020-001001. [28] Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5):467-475. DOI:10.1016/S2213-2600(20)30391-X. [29] Li R, Chen L, Zhang Y, et al. Safety and tolerability of Sintilimab in combination with radiotherapy in treatment naive PD-L1 positive stage ⅠV non-small cell lung cancer (NSCL)[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3 suppl):s72-s73. DOI:10.1016/j.ijrobp.2020.07.2215. [30] Li J, Wang Y, Tang C, et al. Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer:a phase I trial[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3 suppl):e744. DOI:10.1016/j.ijrobp.2020.07.155. [31] Sett RC, Martin JZ, Castilla-Martinez JF, et al. Immuno-SABR reboots the immune response in patients with metastatic NSCLC and melanoma in progression to anti-PD-1 therapy[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3 suppl):s73-s74. DOI:10.1016/j.ijrobp.2020.07.2217. [32] Bestvina CM, Pointer KB, Karrison T, et al. A phase I trial of concurrent or sequential Ipilimumab, Nivolumab, and stereotactic body radiotherapy in patients with stage ⅠV NSCLC study[J]. J Thorac Oncol, 2022, 17(1):130-140. DOI:10.1016/j.jtho.2021.08.019. [33] Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer[J]. Clin Cancer Res, 2005, 11(2 Pt 1):728-734. [34] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547):373-377. DOI:10.1038/nature14292. [35] Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J]. Cancer Immunol Res. 2013, 1(6):365-372. DOI:10.1158/2326-6066. CIR-13-0115. [36] Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade[J]. Nat Med, 2018,24(12):1845-1851. DOI:10.1038/s41591-018-0232-2. [37] Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy:a synergistic combination[J]. J Clin Invest, 2013, 123(7):2756-2763. DOI:10.1172/JCI69219.
2022, Vol. 31 
